Facile method for delivering chikungunya viral replicons into mosquitoes and mammalian cells

Hui-Chung Lin1,2, Der-Jiang Chiao2, Chang-Chi Lin2,3 & Szu-Cheng Kuo2,3*

Reverse genetics is an important tool in the elucidation of viral replication and the development of countermeasures; however, these methods are impeded by laborious and inefficient replicon delivery methods. This paper demonstrates the use of a baculovirus to facilitate the efficient delivery of autonomous CHIKV replicons into mosquito and mammalian cells in vitro as well as adult mosquitoes in vivo. The efficacy of this approach was verified via co-localization among an eGFP reporter, nsP1, and dsRNA as well as through the inhibition of an RNA-dependent RNA polymerase (RdRp) null mutation (DDAA) in nsP4, or the treatment of a known antiviral compound (6-azauridine). We also investigated the correlation between CHIKV replicon-launched eGFP expression and the effectiveness of CHIKV replicon variants in inducing IFN-β expression in human cell lines. This delivery method based on a single vector is applicable to mosquito and mammalian cells in seeking to decipher the mechanisms underlying CHIKV replication, elucidate virus–host interactions, and develop antivirals. This study presents an effective alternative to overcome many of the technological issues related to the study and utilization of autonomous arbovirus replicons.

Chikungunya virus (CHIKV) is an old-world alphavirus of the Togaviridae family grouped genetically within the Semliki Forest virus complex1, which is transmitted by Aedes mosquitoes. CHIKV infection generally causes fever, joint pain, skin rash, and arthralgia, and is in some cases fatal2. In the 1950s, human cases were first reported in Africa, with Aedes mosquitoes identified as the primary vector of the sylvatic cycle3,4. Following a subsequent outbreak in 2004, researchers determined that the virus had expanded into novel ecological niches5. Rising global temperatures and wide-scale transportation are raising further concerns about the spread of CHIKV, as there are at present no effective vaccines or drugs for treating the infection5,6. CHIKV is an enveloped virus measuring roughly 70 nm in diameter with an 11.8 kb single-stranded, positive-sense RNA genome1. The genome of CHIKV comprises a 5′ cap untranslated region (UTR), followed by two open reading frames (ORF) encoded four non-structural proteins (nsP1–4), five structural proteins (C–E3–E2–6K–E1), and a 3′ terminal poly-A tail7. Like other alphaviruses, the polyproteins of four non-structural proteins (nsP1–4) of CHIKV comprise the viral replication machine1,8. Processing non-structural polyproteins to form the nsP1/P23/nsP4 replicase complex results in the production of genomic and subgenomic RNAs9. Subgenomic mRNA transcribed from the subgenomic promoter (accumulating to 10⁶ molecules per cell) is involved in the translation of structural proteins and virion assembly. CHIKV is transmitted from mosquitoes into mammals; however, the characteristics of the alphavirus infection differ in the two hosts. Alphavirus growth in mosquito cells is characterized by non-cytopathic effect (CPE) and persistency9,6. Conversely, alphavirus proliferation in vertebrate cells quickly induces host shut-off and CPE related to viral proteins10. The characteristics of alphavirus infection can be attributed to interactions among viral and cellular factors9. Among the viral factors, RdRp mutant (DDAA) in nsP4 prevents CHIKV replicons from replicating (in both mammalian and mosquito cells), whereas G1332V mutation in the nsP2 can lead to a 60-fold increase in replication (in C6/36 cells in trans)12. nsP2 mutations in mammalian cells are also associated with the attenuation of type I interferon expression13–16. Unraveling the mechanisms underlying host-virus interactions could conceivably be of value in the development of countermeasures aimed at blocking alphavirus transmission. Autonomously replicating replicons lacking the structural proteins necessary for viral particle formation

1Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan. 2Institute of Preventive Medicine, National Defense Medical Center, Taipei 11490, Taiwan. 3Department and Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Taipei 11490, Taiwan. *email: szucheng1234@gmail.com
are often replaced with a reporter gene (e.g., eGFP). Viral replicons capable of recapitulating various steps of the replication cycle without using a live virus could increase accessibility. Transfection of DNA- and RNA-based alphavirus replicons is commonly used to investigate viral replication and assess the efficacy of vaccines and antivirals12,17–23. 6-azauridine (6-AU) has been used as an antiviral against CHIKV infection to evaluate the expression of CHIKV replicon-mediated reporter gene23. Virus-based alphavirus replicons have also been established to improve the efficiency of replicon delivery into mammalian cells24–26. At present, we understand far less about mosquito-alphavirus interactions than vertebrate-alphavirus interactions, due largely to the low efficiency of nucleic acid-based replicon delivery27 and a lack of suitable virus-based replicon systems. The recombinant baculovirus (Bac-CMV/SFV-EGFP) developed by Pan et al. exhibited pronounced SFV replicon-launched eGFP expression in mammalian cells25. The human cytomegalovirus (CMV) promoter has been extensively utilized for transgene expressions in mammalian cells, and has been used as a functional shuttle allowing the rescue of infectious clones of West Nile virus from C6/36 cell28. Previous studies have demonstrated the efficiency of using baculovirus to deliver heterologous genes into mosquito cells (BacMos)29. In the current study, we demonstrated the use of a baculovirus for the efficient delivery of autonomous CHIKV replicons into the mosquito and mammalian cells in vitro (hereafter referred to as dual-host cells) as well as adult mosquitoes in vivo.

Results

In vitro functional analysis. We established a method for the efficient delivery of autonomous CHIKV replicons into mosquito and mammalian cells in order to assess the self-replicating CHIKV replicon-mediated expression of eGFP (Fig. 1a). Recombinant baculovirus bears a CMV promoter-directed wild type (WT/eGFP) or CHIKV replicon variant (G1332V/eGFP and DDAA/eGFP) containing the eGFP gene under the transcription control of CHIKV 26S subgenomic promoter (Fig. 1b). To determine whether the CHIKV replicon was functional, two mammalian cells (U2OS and HEK293T) and two mosquito cells (AP61 and C6/36) were serially transduced with WT/eGFP. The results (Figs. 2, 3) indicate the strong dose-dependency of eGFP expression in mosquito and mammalian cells, which was particularly pronounced in mosquito cells. Note that eGFP levels obtained from mosquito cells should far exceed those obtained from mammalian cells. The most pronounced eGFP expression was detected in WT/eGFP-transduced AP-61 cells. All transduced cells except C6/36 cells presented eGFP expression with dose-dependency proportional to the MOI. Note that at MOIs of 5 and 10, WT/eGFP-transduced C6/36 cells were serially transduced with WT/eGFP. The results (Figs. 2, 3) indicate the strong dose-dependency of eGFP expression in mosquito and mammalian cells, which was particularly pronounced in mosquito cells. Note that eGFP levels obtained from mosquito cells should far exceed those obtained from mammalian cells. The most pronounced eGFP expression was detected in WT/eGFP-transduced AP-61 cells. All transduced cells except C6/36 cells presented eGFP expression with dose-dependency proportional to the MOI. Note that at MOIs of 5 and 10, WT/eGFP-transduced C6/36 cells presented a rounded morphology; however, at an MOI of 10, WT/eGFP-transduced AP-61 cells appeared normal. This is an indication that C6/36 cell are perhaps more sensitive to WT/eGFP transduction than are AP-61 cell. Next, to examine the correlation of eGFP expression and CHIKV replication, immunofluorescence assay (IFA) was conduct to detect eGFP, dsRNA (intermediate of CHIKV replication) and nsP1(viral protein of CHIKV) in transduced AP-61 cells. We also observed the specific co-localization of eGFP, dsRNA and nsP1 in WT/eGFP-transduced AP-61 cells (Fig. 4), indicating RNA replication. To confirm the identity of the autonomous CHIK replicon, we performed functional analysis of IVT-RNA from WT/eGFP. The results (Fig. S1) revealed a high eGFP-positive ratio in IVT-RNA-electroporated BHK-21 cells, indicating the successful expression of eGFP by self-amplified RNA transcripted from the transfer vector of WT/eGFP. Taken
Figure 2. Autonomous CHIKV replicon-mediated expression of eGFP in baculovirus transduced into mosquito cell lines, AP-61 (a) or C6/36; (b) cells were transduced using WT/eGFP at indicated MOIs of 0, 1, 5 or 10 in triplicate. At 2 dpt, eGFP-expressing cells were photographed using green (upper panels) or bright field (lower panels) filters. Expression levels of eGFP were quantified (right part). Error bars represent the standard deviation.

Figure 3. Autonomous CHIKV replicon-mediated expression of eGFP via baculovirus transduction in mammalian cell lines, U2OS (a) or HEK293T (b) cells via transduction with WT/eGFP at indicated MOIs of 0, 1, 5 or 10 in triplicate. At 2 dpt, eGFP-expressing cells were photographed using green (upper panels) or bright field (lower panels) filters. Expression levels of eGFP were quantified (right part). Error bars represent the standard deviation.
together, these results revealed that the autonomous CHIKV replicon is easily delivered into mosquito as well as mammalian cells using a single baculovirus vector.

**Evaluation of antiviral targeting CHIKV replicon.** In order to confirm the correlation of eGFP expression and CHIKV replication, we assessed the efficacy of this proposed system in antiviral assays by examining the inhibition effect of 6-AU on CHIKV replicon-launched eGFP expression. The eGFP expression was assessed after culturing WT/eGFP-transduced AP-61 cells as well as WT/eGFP- or CMV-GFP-transduced U2OS cells (as a control) in the presence of 6-AU at specified dilutions. As shown in Fig. 5a, 6-AU treatment reduced eGFP expression in WT/eGFP-transduced U2OS cells in a dose-dependent manner; however, it had no effect on eGFP expression in CMV-GFP-transduced U2OS cells. We also calculated the 50% inhibitory concentration (IC50) and 50% cytotoxicity concentration (CC50) of 6-AU in U2OS cells at concentrations of 1 μg/ml and > 10 μg/ml. Interestingly 6-AU was shown not to affect CHIKV replicon-launched eGFP expression in AP-61 cells (Fig. 5b). Overall, 6-AU exhibited a mammalian cell-biased inhibitory effect on baculovirus-mediated CHIKV replicon replication. Note that these results are in line with those obtained in previous studies on mammalian cells. Taken together, our findings further support the CHIKV replicon-mediated eGFP expression and suggest that this proposed replicon system could be utilized for the evaluation of antiviral treatments.

**Evaluating the functionality of CHIKV replicon variants in dual-host cells.** To evaluate the functionality of CHIKV replicon for eGFP expression, recombinant baculoviruses bearing either a null functional
DDAA mutation or enhanced G1332V mutation (Fig. 1b) were constructed. CHIKV replicon-launched eGFP expression levels of WT/eGFP, G1332V/eGFP, and DDAA/eGFP were examined in mosquito and mammalian cell lines. As shown in Figs. 6 and 7, eGFP signals were detected in all G1332V/eGFP-transduced dual-host cells at 2 days post transduction (dpt). Interestingly, eGFP intensity in G1332V/eGFP-transduced HEK293T and C6/36 cells was significantly higher than WT/eGFP transduced those both cells. By contrast, the expression level of eGFP of WT/eGFP was extremely significant higher than eGFP level of G1332V/eGFP in U2OS cells. The eGFP intensity of G1332V/eGFP was lower than that of WT/eGFP at 5 and 7 dpt in AP-61 cells (Fig. 8a). As expected, no eGFP signal was observed in either DDAA/eGFP-transduced mosquito and mammalian cell lines, which indicates that eGFP expression can be attributed to the functional CHIKV replicon. In time-course assays (Fig. 8), we observed the accumulation of intense eGFP signals in all transduced mosquito cells throughout incubation from 1 to 7 dpt. Note that in transduced mammalian cells, eGFP signals of peak intensity were observed at 2 dpt. Levels of eGFP expression were higher in transduced mosquito cells (10–20 × 10^3 RFU) than in transduced mammalian cells (< 10 × 10^3 RFU) at 7 dpt. To determine whether the pattern of CHIKV replicon-launched eGFP expression was associated with innate immunity status, we measured the level of IFN-β mRNA in transduced human cells (U2OS and HEK293T) at 4 and 24 post-transduction (hpt) using qRT-PCR. As shown in Fig. 9, at 4 hpt, IFN-β mRNA levels in WT/eGFP- and G1332V/eGFP-transduced human cells were significantly higher than in DDAA/eGFP-transduced human cells; however, we did not observe a statistically significant difference between WT/eGFP- and G1332V/eGFP-transduced human cells. At 24 hpt, IFN-β mRNA levels in G1332V/eGFP-transduced U2OS and HEK293T cells were significantly higher than in WT/eGFP transduced cells; however, we did not observe a statistically significant difference between WT/eGFP- and DDAA/eGFP-transduced human cells. This indicates that G1332V/eGFP is associated with the potency of IFN-β mRNA induction. Taken together, these results demonstrate the efficacy of the proposed replicon system in characterizing CHIKV replicon variants in terms of replicon-launched eGFP expression (replication) and the potency of IFN-β induction.

**Functional analysis of in vivo delivery system into mosquitoes.** The efficacy of the proposed in vivo delivery system was evaluated by intrathorically injecting WT/eGFP, G1332V/eGFP, or DDAA/eGFP into adult mosquitoes of two species (A. aegypti and A. albopictus). Those eGFP signals were observed in both species of mosquito following injection with WT/eGFP or G1332V/eGFP. Time course results (data not shown) revealed that eGFP signals can be attributed to gene turn-on rather than carry over. As shown in Fig. 10a, the eGFP signals at 5 dpt were more pronounced in WT/eGFP- or G1332V/eGFP-injected mosquitoes than in DDAA/eGFP-injected mosquitoes. Of note, the eGFP signals were more pronounced in A. aegypti mosquitoes than in A. albopictus mosquitoes. As expected, no eGFP signals were detected in DDAA/eGFP-injected mosquitoes. Quantitative results (Fig. 10b) of eGFP intensity confirm that levels of eGFP signal in WT/eGFP-injected both mosquitoes were significantly
higher than eGFP level in corresponding G1332V/eGFP-injected mosquitoes. These results demonstrate the efficacy of the proposed system in the in vivo delivery of functional CHIKV replicons into adult mosquito hosts.

**Discussion**

Reverse genetics is an important tool in the elucidation of viral replication and the development of novel vaccine strategies. Note however that nearly all reverse genetics systems are based on the cells of vertebrates, despite the fact that the lifecycle of arboviruses involves mosquitoes as well as mammals (i.e., invertebrates and vertebrates). Thus, a simple universal method by which to introduce genomes or replicons into both mammalian and mosquito cells could facilitate the study of functional genomics pertaining to arboviruses as well as the prediction of outbreaks and the development of countermeasures. Viral vectors that are accessible to mammalian cells in vitro may provide an efficient system for the autonomous delivery of replicons into target cells; however, no such system has been reported specifically for mosquito cells. Furthermore, most reverse genetics systems designed for positive-sense single-stranded RNA viruses associated with the *Aedes* mosquito cell line are based on the transfection or electroporation of DNA- and RNA-based replicons. Note that the efficiency of the RNA delivery systems is very low (0.2–10%). One study reported an improved transfection protocol to
overcome these technological issues for insect cells. Efforts to use reverse genetics for arboviruses will require a new approach to the delivery of replicons into mosquitoes and mammalian cells.

In the current study, we developed a baculovirus-mediated CHIKV replicon delivery system (Fig. 1), in which a CHIKV cDNA replicon is delivered into mosquitoes and mammalian cells via transduction under the control of a CMV promoter. The use of a single baculovirus vector eliminates the trouble and expense of capped IVT-RNA preparation and electroporation. Baculovirus/CHIKV replicon-launched eGFP expression was validated via co-localization among an eGFP reporter, nsP1, and dsRNA (Fig. 4) as well as inhibition via 6-AU treatment (Fig. 5) or the introduction of a DDAA mutation in RdRp (Figs. 6, 7). CHIKV replicon-launched eGFP expression was more pronounced in mosquito cells than in mammalian cells (Figs. 2, 3, 8), due perhaps to a lower rate of transduction in mammalian cells. eGFP expression was more pronounced in transduced-U2OS cells than in transduced-HEK293T cells, due largely to the efficiency of baculovirus transduction.

Alphavirus nsP2 virulence can be characterized in terms of the effect on the host antiviral response via two down-regulatory pathways: (i) IFN-β transcription via global host shutoff and (ii) JAK-STAT signaling via inhibition of STAT1 phosphorylation and/or nuclear translocation. Interestingly, this study demonstrated that the G1332V mutant (nsP2) is associated with an increase in eGFP expression in innate immunity-deficient C6/36 (from 1 to 7 dpt) and HEK293T cells (at 2 and 3 dpt) and a decrease in eGFP expression in AP-61 (at 5 and 7 dpt) and U2OS cells (at 2 and 3 dpt) (Fig. 6, 7, 8). This is consistent with previous reports that the replication/transcription of CHIKV G1332V mutant did not alter activity in mammalian cells, but induced a 60-fold increase in C6/36 cells. Researchers have reported a variety of defects in the innate immune responses to adenovirus infection in U2OS cells. However, RNA viral infections tend to upregulate IFN-β expression in U2OS cells. The nsP2 G1332V mutant is a potent inducer of IFN-β rapidly activated ISGs in U2OS cells, resulting in the inhibition of CHIKV replicon-launched eGFP expression. G1332V/eGFP-transduced cells (C6/36 and HEK293T) presented a significant increase in replication (eGFP expression), due perhaps to the delayed cleavage of nsP2-nsP3. In C6/36 cells (incompetent innate immunity), the restriction of innate immunity could be relieved resulting in eGFP expression levels of G1332V/eGFP higher than WT/eGFP. HEK293T cells retained their transcriptional pro-inflammatory response but lost their ability to secrete type 1 IFN. In HEK293T cells, G1332V/eGFP transduction also induced high eGFP expression as well as IFN-β mRNA expression, albeit without a concomitant increase in secretion. These findings could imply the conservation of unknown evolutionary mechanisms in mosquito and mammalian cells. Previous studies have reported that point mutations in S-adenosyl-l-methionine (SAM)-dependent RNA methyltransferase-like (SAM MTase-like) domain impairs the ability of nsP2 to induce transcriptional shutoff. Likewise, CHIKV G1332V point mutations located in the SAM MTase-like domain could have a deleterious effect on the ability of nsP2 to induce transcriptional shutoff. Another nsP2 mutant...
(P726G) in SINV also resulted in elevated IFN-β production despite limited virus propagation in vivo. Functional nsP2 in WT/eGFP was shown to induce global transcriptional shutoff via RPB1 degradation, which prevented activation of the transcription-dependent IFN-β response and JAK-STAT signaling and also induced cell death. Conversely, the nsP2 G1332V mutant without the above functionalities was shown to strongly induce IFN-β expression. In cases of SINV infection, the G1332V mutant associated nonfunctional nsP2 strongly promoted α/β interferon production by preventing infected cells from downregulating cellular transcription.

Note however that replication of the SINV G1332V mutant was defective in mosquito cells but not in vertebrate cells. The nsP1/nsP2/ nsP3 cleavage domains play a critical role in regulating cellular antiviral response induced by the Ross River Virus or Sindbis virus. However, the role of the nsP1/nsP2/ nsP3 cleavage domains of CHIKV has yet to be elucidated. In the current study, we demonstrated that the nsP2/ nsP3 cleavage domain drives the CHIKV-induced IFN-β response.

In CHIKV-eGFP based assays, the IC₅₀ value for 6-AU was approximately 1 μg/ml (4 μM) (Fig. 5a), which is in good agreement with previous reports on reporter-based stable CHIKV replicon cell lines and CHIKV replication in Vero cells. Note that 6-AU did not affect eGFP expression in mosquito cells. Previous studies reported that 6-AU exhibits a moderate anti-arboviral activity in mammalian cells but not in mosquito cells, indicating fundamental differences in the host-CHIKV or drug-host interactions. The transient replicon system developed in the current study could be a valuable tool by which to perform high-throughput antiviral screening, optimize antiviral activities, and elucidate antiviral mechanisms.
To the best of our knowledge, this is the first study to report the in vivo delivery of functional CHIKV replicons into adult mosquitoes (Fig. 10). Following injection with WT/eGFP or G1332V/eGFP, eGFP expression was more pronounced in *A. aegypti* than in *A. albopictus* (Fig. 10a), due to differences in vector competence and/or CMV activity. The eGFP signals in WT/eGFP-injected both mosquitoes were significantly higher than eGFP level in corresponding G1332V/eGFP-injected mosquitoes (Fig. 10b), due perhaps to the functional nsP2 restriction of innate mosquito immunity to WT CHIKV replication. Note that we have also conducted in vivo assays using another reporter of a near-infrared fluorescent protein (iRFP682) in mice; however, the results to date have been unsuccessful, due perhaps to the sensitivity of baculovirus and/or the restriction of innate immunity. Efforts to elevate MOI and thereby permit the detection of RFP682 expression in mice are currently on-going.

Alphavirus replicons have previously been used to induce heterologous protein expression in mammalian cells. This is the first study to demonstrate the use of a baculovirus for the efficient delivery of autonomous CHIKV replicons into mammalian and mosquito cells in vitro as well as adult mosquitoes in vivo. The peak CHIKV replicon-launched eGFP expression levels were observed at 2 dpt in mammalian cells and 7 dpt in mosquito cells. Persistent replicon-launched eGFP expression exceeding 30 days (data not shown) highlights the potential of the proposed replicon system for heterologous protein expression using mosquito cells. Previous study has demonstrated that baculovirus does not replicate in mosquito cell line. The continuous increase in eGFP expression in transduced mosquito cells likely results in persistency of CHIKV replicon. Additionally, combining baculovirus/CHIKV systems may make it possible to create a single-round infectious virus from dual-host cells as an alternate approach to vaccine development. The proposed scheme allows the efficient delivery of replicons into mosquito and mammalian cells using a single vector to facilitate analysis of CHIKV replication and the development of treatments. The proposed replicon system was shown to improve the utility of alphavirus expression systems, particularly in mosquito cells. Due to inconsistencies in the persistent infectivity of alphaviruses in mosquitoes and mammalian cells, the proposed system could conceivably be used to develop a new generation of systems for alphavirus replicon-based protein expression in mosquito cells. This system also opens the door to the development of alphavirus VRP packages based on mosquito cells, while facilitating the in vivo delivery of alphavirus replicons into mosquitoes.

**Methods**

**Cells and viruses.** Cells from mosquito cell line AP-61 (*Aedes pseudoscutellaris*) were cultured in Leibovitz L-15 medium (Gibco) with 10% fetal bovine serum (FBS) (Gibco) and 1% antibiotic–antimycotic (Gibco) at 28 °C. Cells from the mosquito cell line C6/36 (*Aedes albopictus*) (ATCC® CRL-1660™) were cultured in RPMI 1640 Medium (Gibco) with 1% penicillin/streptomycin (Gibco) and 10% FBS (Gibco) at 28 °C under 5% CO2. U2OS cells (ATCC HTB-96), HEK293T cells (ATCC® CRL-1573™) cells grown in Dulbecco's modified Eagle medium (DMEM) (GIBCO) containing 1% GlutaMAX™ (Gibco), 1% penicillin/streptomycin (Gibco) and 10% FBS (Gibco) at 37 °C in 5% CO2. BHK-21 cells (ATCC® CCL-10™) were cultured in Minimum Essential Media (MEM)(Gibco) containing 1% GlutaMAX™ (Gibco), 1% MEM NEAA (Gibco), 1% Sodium Pyruvate (Gibco), 1% penicillin/streptomycin (Gibco) and 10% FBS (Gibco) at 37 °C in 5% CO2.

**Generation of recombinant baculoviruses for CHIKV replicons.** In constructing a CHIKV replicon transfer vector, we first cloned the glycoprotein gene of Vesicular stomatitis virus (VSVG) (GenBank: J02428.1), which was amplified via PCR using the viral DNA of CellLight™ Early Endosomes-RFP (Invitrogen, Carlsbad, CA, USA) as a template with a pair of primers (forward: 5′-TTGGGATCTTTGAACATAATGAGG-3′; reverse: 5′-AGGGGATCCGCTTAAACCCAGTGGCAGGATTATGTTGTTTCTG-3′ inserted into the BamHI and SpIi sites of the pFastBac1 vector (Invitrogen, Carlsbad, CA, USA) to create the plasmid, pFastBac1-VSVG-Spf-Per. A synthetic 9.5-kb CHIKV replicon-GFP DNA fragment derived from CHIKV strain LR2006_OPY1 (GenBank: KT449801) with structural gene (268) substitution and green fluorescent protein (EGFP) also subcloned into the SgfI and PmcI sites of pFastBac1-VSVG. The resulting plasmid is hereafter referred to as the pFastBac1-VSVG-CHIKV replicon-GFP of the CHIKV replicon transfer vector. Both CHIKV replicon transfer vectors of GAA and G1332V mutants were created by site-directed mutagenesis using PCR based on the sequence of pFastBac1-VSVG-CHIKV replicon-GFP. In constructing the GAA mutant, two PCR fragments of 4.9-kb (forward: 5′-GCCCTACGACCATGATGAGG-3′; reverse: 5′-CCATGT ATTATGTTGCGCGCCGATGAAAGCC-3′) and 0.4-kb (forward: 5′-GGCCCTATGCGCGCGCCGCAAATAATCGAGG-3′; reverse: GCAAATAGTTAGCCGCGCGCGTAGTAGG-3′) were assembled with a large fragment of pFastBac1-VSVG-CHIKV replicon-GFP EcoRI-NotI using the NEBuilder HiFi DNA Assembly. In constructing the G332V mutant, two PCR fragments of 1.9-kb (forward: 5′-GCCCTACGACCATGATGAGG-3′; reverse: 5′-CCATGT ATTATGTTGCGCGCCGATGAAAGCC-3′) and 3.4-kb (forward: 5′-GCCCTACGACCATGATGAGG-3′; reverse: GCAAATAGTTAGCCGCGCGCGTAGTAGG-3′) were assembled with a large fragment of pFastBac1-VSVG-CHIKV replicon-GFP EcoRI-NotI using the NEBuilder HiFi DNA Assembly. The transfer vectors of both mutants were confirmed by DNA sequencing via PCR. The generation of recombinant baculoviruses for CHIKV replicon was performed in accordance with the protocol of the Bac to Bac expression system (Invitrogen, Carlsbad, CA, USA). Viral titers were determined using the BacPAK™ Baculovirus Rapid Titer Kit (Takara Bio USA, Inc) in accordance with the manufacturer's instructions.

**Baculovirus transduction.** Mosquito or mammalian cells were seeded in 24-well plates (2 × 10⁵ cells/well or 1 × 10⁶ cells/well) and in 96-well plates (2 × 10⁴ cells/well or 1 × 10⁵ cells/well). On the following day, cells were transduced with baculovirus at an indicated multiplicity of infection (MOI) in phosphate-buffered saline, pH 7.4 (PBS) (Gibco) at 28 °C or 37 °C for 1 h (hr). Cells were washed using PBS once prior to the addition of growth culture medium. The cells were cultured for various durations as indicated.

https://doi.org/10.1038/s41598-021-91830-y
In generating rabbit anti-nsP1 serum, a 911-bp NcoI–SmaI fragment (AF369024, 637–1548) of partial nsP1 gene from the pFastBac1- VSVG-CHIKV replicon-GFP was subcloned into the restriction enzyme sites of pET32c. The expression, purification, and rabbit immunization of recombinant nsP1 were performed in accordance with methods described in a previous report57. AP-61 cells were transduced using WT/eGFP at an MOI of 5. At 4 dpt, cells were fixed and incubated using the above-mentioned rabbit anti-nsP1 serum (1:100) or Mab anti-GFP antibodies (Santa Cruz Biotechnology, Inc.) (1:100) and mouse anti-dsRNA antibody (SCICONS) for 1 h. Cells were subsequently washed three times using PBS and incubated with either Alexa Fluor 594-conjugated secondary antibodies or Alexa Fluor 488-conjugated secondary antibodies as well as Hoechst 33342 (10 µM) for 1 h. After a final wash using PBS, images of cells were captured using an inverted fluorescence microscope (DMi8 Microscope, Leica Microsystems).

**eGFP quantification.** Cells in triplicate collected from 24-well plates were lysed using 200 µL/well RIPA buffer (‘Thermo Scientific”). The eGFP expression was measured using DS-11 FX + spectrophotometer/fluorometer (DeNovix, USA) in accordance with the manufacturer’s instructions. Three independent experiments in time course assay were performed with very similar results, and the data presented represent the results from one independent experiment.

**Inhibition assay.** U2OS and AP-61 cells were seeded in 24-well plates at a density of 1 × 10⁴ cells/well. On the following day, U2OS cells were transduced using either WT/eGFP or CMV-GFP (CellLight™ Early Endosomes-GFP, Invitrogen) as a negative control, respectively at an MOI of 5 or 1. AP-61 cells were transduced using WT/ eGFP at an MOI of 1. Transduced cells were cultured in triplicate using growth medium in the presence 6-AU (Sigma-Aldrich) at various indicated concentrations. Following incubation for 24 h, cells were subjected to eGFP quantification assay. In cell viability assays, U2OS or AP-61 cells were seeded in 96-well plate at a density of 2 × 10⁴ cells/well. On the following day, cells were cultured in triplicate using growth medium in the presence 6-AU at various concentrations for 24 h. Cell viability was determined using the Cell Counting Kit-8 kit (Enzo) in accordance with the manufacturer’s instructions. Absorbance at 450 nm was measured using a microplate reader Infinite® 200 PRO (Tecan Trading, Ltd., Switzerland). Cell viability was evaluated in terms of absorbance at various doses divided by the absorbance at 0 µg/ml. Three independent experiments were performed with very similar results, and the data presented represent the results from one independent experiment.

**Quantitative analysis of IFN-β mRNA.** U2OS or HEK293T cells (24-well plate) were transduced with the indicated recombinant baculovirus at an MOI of 10. Total RNA was harvested at 4 or 24 hpt using a Monarch® Total RNA Miniprep Kit (NEB). One-step, quantitative RT–PCR was performed using the one-step reverse transcriptase PCR (RT-PCR) kit (Qiagen) in a total volume of 25 µl. qRT–PCR was conducted using the ABI StepOnePlus Real Time PCR System (Applied Biosystems) in triplicate. The primer sequences used in this assay were as follows: HPRT-F, 5′-ATC AGA CTG AAG AGC TAT TGT AAT GA-3′; HPRT-R, 5′-ATG CTG AAA TTG TTC TC-3′; and IFN-b-F, 5′-ACA GGA GCT TCT GAA GCT-3′; IFN-b-R, 5′-GGT GAC TCC TAA AGA TGT GC-3′. Assessment of IFN-β expression was based on relative quantification (RQ) using the comparative critical threshold (CT) value method. IFN-β expression was normalized to hypoxanthine–guanine phosphoribosyltransferase (HPRT) encoded in humans by the endogenous control gene HPRT1. Fold changes were calculated using the ddCt algorithm based on WT/eGFP samples as a reference. Two independent experiments were performed with very similar results, and the data presented represent the results from one independent experiment.

**Mosquito transduction in vivo.** Adult A. aegypti (Kaoshing strain) and A. albopictus (Chung-Ho strain) mosquitoes were reared at 27 °C under 80% humidity with a 12-h light/dark cycle. Cold-anesthetized mosquitoes were insonated with pooled sera at a dose of 5 × 10⁶ plaque forming units (pfu)/mosquito. At 5 dpt, cold-anesthetized mosquitoes were photographed using an IX71 inverted fluorescence microscope (Olympus). The levels of eGFP intensity of images was quantitated with Image J 1.53e version. We narrowed the hue tone of the color threshold (54 to 112) for the specific intensity of green color. The methods of quantification are outlined in the Image J documentation: ‘Image → Adjust → Color Threshold → Measure’. The eGFP intensity was defined as (Area X Mean fluorescence of readings). For calculation of relative intensities, the pixel intensity was normalized with the fluorescent signal of PBS-injected mosquitoes. Two mosquitoes were analyzed for each genotype.

**Statistical analysis.** Data were analyzed using GraphPad Prism 6.01 software. Data was assessed for statistically significant differences using a two-tailed, unpaired t-test. A p value < 0.05 was considered statistically significant. p values were indicated as follows: ns, not significant; *p < 0.05, significant; **p < 0.01, highly significant; ***p < 0.001 and ****p < 0.0001, extremely significant.
40. Fras, J. J. et al. Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling. J. Virol. 84, 10877–10887. https://doi.org/10.1128/JVI.00949-10 (2010).

41. Simmons, J. D. et al. Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff. J. Virol. 83, 10571–10581. https://doi.org/10.1128/JVI.01041-09 (2009).

42. Brackney, D. E. et al. Co6/36 Aedes albopictus cells have a dysfunctional antiviral RNA interference response. PLoS Negl. Trop. Dis. 4, e856. https://doi.org/10.1371/journal.pntd.0000856 (2010).

43. Ferreira, C. B. et al. Lentiviral vector production titer is not limited in HEK293T by induced intracellular innate immunity. Mol. Ther. Methods Clin. Dev. 17, 209–219. https://doi.org/10.1016/j.omtm.2019.11.021 (2020).

44. Laredj, L. N. & Beard, P. Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells. J. Virol. 85, 13133–13143. https://doi.org/10.1128/JVI.05407-11 (2011).

45. Thompson, M. R. et al. Interferon γ-inducible protein (IFI) 16 transcriptionally regulates type I interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses. J. Biol. Chem. 289, 23586–23581. https://doi.org/10.1074/jbc.M114.554147 (2014).

46. Gorchakov, R. et al. A new role for ns polyprotein cleavage in Sindbis virus replication. J. Virol. 82, 6218–6231. https://doi.org/10.1128/jvi.02624-07 (2008).

47. Gorchakov, R., Frolova, E. & Frolov, I. Inhibition of transcription and translation in Sindbis virus-infected cells. J. Virol. 79, 9397–9409. https://doi.org/10.1128/jvi.79.15.9397–9409.2005 (2005).

48. Liu, X. et al. Decreased virulence of Ross River virus harboring a mutation in the first cleavage site of nonstructural polyprotein is caused by a novel mechanism leading to increased production of interferon-inducing RNAs. MBio https://doi.org/10.1128/mBio.00044-18 (2018).

49. Cruz, C. C. et al. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology 399, 1–10. https://doi.org/10.1016/j.viro.2009.12.031 (2010).

50. Briolant, S., Garin, D., Scaramozzino, N., Jouan, A. & Crance, J. M. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res. 61, 111–117. https://doi.org/10.1016/j.antiviral.2003.09.005 (2004).

51. Pascoalino, B. S., Courtemanche, G., Cordeiro, M. T., Gil, L. H. & Freitas-Junior, L. Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library. PLoS ONE 5, 2523. https://doi.org/10.1371/journal.pone.0019641 (2010).

52. Crance, J. M., Scaramozzino, N., Jouan, A. & Garin, D. interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 58, 73–79. https://doi.org/10.1016/j.antiviral.2002.12.003 (2003).

53. Hofmann, C. & Strauss, M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 5, 531–536. https://doi.org/10.1038/sj.gt.3300607 (1998).

54. DiCiommo, D. P. & Bremner, R. Rapid, high level protein production using DNA-based Semliki Forest virus vectors. J. Biol. Chem. 273, 18060–18066. https://doi.org/10.1074/jbc.273.29.18060 (1998).

55. Lijstroom, P. & Garoff, H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnol. (N. Y) 9(2), 1356–1361. https://doi.org/10.1038/nbt1291-1356 (1991).

56. Kuo, S. C. et al. Cell-based analysis of Chikungunya virus membrane fusion using baculovirus-expression vectors. J. Virol. Methods 175, 206–215. https://doi.org/10.1016/j.jviromet.2011.05.015 (2011).

Acknowledgements
This research was funded by the NHRI (NHRI-109A1-MRCO-08202003 and NHRI-110A1-MRCO-08212101), the MOST (MOST 109-2327-B-016-003) and the NDMC (MAB-107-046 and MAB-110-075).

Author contributions
Conceptualization, S.-C.K.; data curation, all; investigation, H.-C.L, C.-C.L., and S.-C.K.; methodology, H.-C.L, D.-J.C., and C.-C.L.; project administration, S.-C.K.; supervision, S.-C.K.; writing—original draft, H.-C.L, C.-C.L., and S.-C.K.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-91830-y.

Correspondence and requests for materials should be addressed to S.-C.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021